Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Glabellar Frown Lines

20 clinical trials

23 products

Clinical trial
A Randomised, Double-blind, Multi-centre, Phase II, Optimal Dose-finding Study to Determine the Safety and Efficacy of MT10109 (Clostridium Botulinum Toxin Type A) in Subjects With Moderate to Severe Glabellar Lines in Comparison to BOTOX®
Status: Completed, Estimated PCD: 2012-03-30
Product
MT10109
Product
MBA-P01
Clinical trial
Open-label, Single Group, Multi-center, Repeat-dose Long-term Extension Study to Evaluate the Long-term Safety and Efficacy of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2023-05-30
Product
BoNT-A
Clinical trial
Open-label Study to Assess Aesthetic Improvement Following Treatment With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
Status: Completed, Estimated PCD: 2023-03-31
Product
QM1114-DP
Clinical trial
A Phase IV, Randomized, Interventional, Study to Assess Subject Treatment Session Perception and Investigator Treatment Experience of Alluzience and Vacuum-Dried Botulinum Neurotoxin Type A for Aesthetic Use
Status: Completed, Estimated PCD: 2022-10-12
Product
Alluzience
Clinical trial
A Phase 1/2 Study to Establish An Initial Therapeutic Range and Safety Data for AI-09 in the Treatment of Glabellar Lines
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
Vehicle
Product
AI-09
Product
NT 201
Clinical trial
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Status: Completed, Estimated PCD: 2021-04-15
Product
Placebo
Product
Botulinum Toxin Neuromodulator
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
Status: Completed, Estimated PCD: 2020-10-02
Clinical trial
A Randomized, Double-Blind, Active-Control, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of "ATGC-110" Compared to "Xeomin®" in Patients Who Need Moderate or Severe Glabellar Line Improvement
Status: Active (not recruiting), Estimated PCD: 2023-02-10
Product
ATGC-110
Product
Xeomin®
Clinical trial
A Phase II, Double Blind, Randomised, Placebo and Active Comparator Controlled Study to Assess the Safety and Efficacy of Three Doses of Dysport RU (20 U, 50 U, and 75 U) Administered as a Single Treatment Cycle to Improve the Appearance of Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2011-09-01
Product
Botulinum toxin type A
Clinical trial
Non-Interventional Post-Authorisation Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
Status: Recruiting, Estimated PCD: 2025-05-01
Product
prabotulinumtoxinA
Clinical trial
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2022-06-22
Clinical trial
A Prospective, Randomized, Double-blind, Multicenter Study to Investigate the Safety and Duration of Effect of Different NT 201 Dose Groups Following the Treatment of Glabellar Frown Lines
Status: Completed, Estimated PCD: 2020-09-10
Clinical trial
Phase II Multi-Ctr, Prospective, Randomized, Double Blind, Active-Controlled Single Treatment Increasing Dose Trial to Study Safety & Duration of Effect of 40U of PrabotulinumtoxinA-xvfs in Adult Subjects for Treatment of Glabellar Lines
Status: Completed, Estimated PCD: 2023-05-22
Product
PrabotulinumtoxinA-Xvfs
Product
OnabotulinumtoxinA
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2020-08-07
Product
Botulinum Toxin
Clinical trial
LONG RUN: LONGitudinal Evaluation and Real-world Evidence of Uniquely Purified incobotulinumtoxinA (Xeomin) in Treatment Naïve Participants
Status: Terminated, Estimated PCD: 2023-05-18
Product
PROTOXIN
Clinical trial
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Compare the Efficacy and Safety of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
Status: Completed, Estimated PCD: 2023-06-20
Product
IncobotulinumtoxinA
Product
Botox®
Clinical trial
Split-Face Study Comparing OnabotulinumtoxinA (Botox) and PrabotulinumtoxinA (Jeuveau) in Treating Glabellar Lines
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Product
PrabotulinumtoxinA
Product
Onabotulinum toxin A
Clinical trial
A Randomized, Parallel-Group Study on the Duration Response of Highly Concentrated On Label Dose (COLD) of Jeuveau® Compared to the On Label Dose and Concentration (OLD) in Subjects With Moderate to Severe Dynamic Glabellar Lines
Status: Completed, Estimated PCD: 2023-06-15
Clinical trial
A Phase 2a Study to Evaluate the Effects of DaxibotulinumtoxinA for Injection on the Treatment of Dynamic Forehead Lines and Glabellar Lines
Status: Recruiting, Estimated PCD: 2025-05-01
Product
DAXXIFY